Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...

For Tina, finally getting a diagnosis of Sjögren’s was a relief. Tina Aswani Omprakash’s hospital bedside table was crowded with an unusual collection of items she regularly used to combat dryness ...

A Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis ...

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...

Cosentyx® (secukinumab) is the first new biologic treatment for hidradenitis suppurativa (HS) in nearly a decade, offering clinically meaningful results across the most debilitating symptoms1,2 ...

Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9 million ...

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...

Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma ...

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction 1 Leqvio provides effective and sustained LDL-C ...